Table III.

Univariate analysis for PFS and OS in diffuse large B cell lymphoma patients treated with CHOP.

	PFS			OS
Variable	HR	95% CI	P-value	HR	95% CI	P-value
Age, ≤60/>60 years	0.802	0.412–1.562	0.528	0.410	0.196–1.037	0.065
Sex, M/F	1.278	0.672–2.494	0.458	1.731	0.744–3.875	0.215
LDH, ≤200/>200 U/l	1.063	0.553–2.069	0.849	0.761	0.321–1.744	0.508
B symptom, yes/no	0.720	0.364–1.338	0.308	0.716	0.288–1.671	0.423
Stage, I–II/III–IV	0.861	0.442–1.637	0.644	0.873	0.376–2.024	0.753
IPI, 0–2/3–4	0.647	0.310–1.193	0.165	0.211	0.085–0.461	<0.001b
ENE, yes/no	0.608	0.309–1.123	0.120	0.688	0.302–1.552	0.372
LMP1, positive/negative	0.341	0.175–0.634	0.001b	0.317	0.156–0.803	0.015a
miR-155, ≤12/>12 fold high expression	0.503	0.261–0.951	0.043a	0.409	0.190–0.977	0.048a

^aP<0.05

^bP<0.001. CI, confidence interval; ENE, extranodal extension; HR, hazard ratio; IPI, international prognostic factors index; LDH, lactate dehydrogenase; LMP1, latent membrane protein 1; miR, microRNA; OS, overall survival; PFS, progression-free survival; CHOP, cyclophosphamide, vincristine, doxorubicin and prednisone.